- Home
- FOXF vs SNDX Comparison
FOXF vs SNDX Comparison
Compare FOXF & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOXF
- SNDX
- Stock Information
- Founded
- FOXF 2007
- SNDX 2005
- Country
- FOXF United States
- SNDX United States
- Employees
- FOXF N/A
- SNDX N/A
- Industry
- FOXF Motor Vehicles
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- FOXF Consumer Discretionary
- SNDX Health Care
- Exchange
- FOXF Nasdaq
- SNDX Nasdaq
- Market Cap
- FOXF 1.2B
- SNDX 1.1B
- IPO Year
- FOXF N/A
- SNDX 2016
- Fundamental
- Price
- FOXF $28.62
- SNDX $13.08
- Analyst Decision
- FOXF Buy
- SNDX Strong Buy
- Analyst Count
- FOXF 6
- SNDX 10
- Target Price
- FOXF $40.33
- SNDX $36.20
- AVG Volume (30 Days)
- FOXF 609.9K
- SNDX 2.7M
- Earning Date
- FOXF 02-20-2025
- SNDX 02-25-2025
- Dividend Yield
- FOXF N/A
- SNDX N/A
- EPS Growth
- FOXF N/A
- SNDX N/A
- EPS
- FOXF 0.26
- SNDX N/A
- Revenue
- FOXF $1,373,579,000.00
- SNDX $16,000,000.00
- Revenue This Year
- FOXF N/A
- SNDX N/A
- Revenue Next Year
- FOXF $4.16
- SNDX $14.15
- P/E Ratio
- FOXF $111.02
- SNDX N/A
- Revenue Growth
- FOXF N/A
- SNDX N/A
- 52 Week Low
- FOXF $26.76
- SNDX $12.06
- 52 Week High
- FOXF $69.47
- SNDX $25.34
- Technical
- Relative Strength Index (RSI)
- FOXF 42.02
- SNDX 41.29
- Support Level
- FOXF $27.67
- SNDX $12.40
- Resistance Level
- FOXF $28.99
- SNDX $13.16
- Average True Range (ATR)
- FOXF 1.12
- SNDX 0.65
- MACD
- FOXF 0.04
- SNDX 0.10
- Stochastic Oscillator
- FOXF 42.13
- SNDX 39.38
About FOXF Fox Factory Holding Corp.
Fox Factory Holding Corp is a designer, manufacturer, and marketer of performance-defining products and systems used predominantly on bikes, Side-by-Sides, on-road vehicles with and without off-road capabilities, off-road vehicles and trucks, ATVs, snowmobiles, specialty vehicles and applications, motorcycles, and commercial trucks. Its business operates under the FOX, FOX RACING SHOX, and RACE FACE brands. Geographically, it derives a majority of revenue from North America and also has a presence in Asia, Europe, and the Rest of the World.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.